225 related articles for article (PubMed ID: 1607000)
1. Pharmacokinetics of meropenem in subjects with renal insufficiency.
Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cefepime in subjects with renal insufficiency.
Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Leroy A; Fillastre JP; Borsa-Lebas F; Etienne I; Humbert G
Antimicrob Agents Chemother; 1992 Dec; 36(12):2794-8. PubMed ID: 1482147
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefonicid in uraemic patients.
Fillastre JP; Fourtillan JB; Leroy A; Ramis N; Lefevre MA; Reumont G; Humbert G
J Antimicrob Chemother; 1986 Aug; 18(2):203-11. PubMed ID: 3759731
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
Chimata M; Nagase M; Suzuki Y; Shimomura M; Kakuta S
Antimicrob Agents Chemother; 1993 Feb; 37(2):229-33. PubMed ID: 8452352
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
Abo El Sooud K
J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
Kelly HC; Hutchison M; Haworth SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():35-41. PubMed ID: 8543497
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
[TBL] [Abstract][Full Text] [Related]
14. Ofloxacin pharmacokinetics in renal failure.
Fillastre JP; Leroy A; Humbert G
Antimicrob Agents Chemother; 1987 Feb; 31(2):156-60. PubMed ID: 3471179
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.
Byun SY; Jeong JW; Choi JH; Lee KP; Youn HY; Maeng HJ; Song KH; Koo TS; Seo KW
J Vet Pharmacol Ther; 2016 Dec; 39(6):560-565. PubMed ID: 27302674
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
[TBL] [Abstract][Full Text] [Related]
19. [Meropenem: pharmacologic advantages of clinical interest].
Domínguez-Gil Hurlé A
Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():32-7. PubMed ID: 9410067
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
